Harari, Daniel
(Department of Biological Regulation, the Weizmann Institute of Science, Rehovot 76100, Israel)
,
Yarden, Yosef
(Department of Biological Regulation, the Weizmann Institute of Science, Rehovot 76100, Israel)
Overexpression of ErbB2, a receptor-like tyrosine kinase, is shared by several types of human carcinomas. In breast tumors the extent of overexpression has a prognostic value, thus identifying the oncoprotein as a target for therapeutic strategies. Already, antibodies to ErbB2 are used in combinatio...
Overexpression of ErbB2, a receptor-like tyrosine kinase, is shared by several types of human carcinomas. In breast tumors the extent of overexpression has a prognostic value, thus identifying the oncoprotein as a target for therapeutic strategies. Already, antibodies to ErbB2 are used in combination with chemotherapy in the treatment of metastasizing breast cancer. The mechanisms underlying the oncogenic action of ErbB2 involve a complex network in which ErbB2 acts as a ligand-less signaling subunit of three other receptors that directly bind a large repertoire of stroma-derived growth factors. The major partners of ErbB2 in carcinomas are ErbB1 (also called EGFR) and ErbB3, a kinase-defective receptor whose potent mitogenic action is activated in the context of heterodimeric complexes. Why ErbB2-containing heterodimers are relatively oncopotent is a function of a number of processes. Apparently, these heterodimers evade normal inactivation processes, by decreasing the rate of ligand dissociation, internalizing relatively slowly and avoiding the degradative pathway by returning to the cell surface. On the other hand, the heterodimers strongly recruit survival and mitogenic pathways such as the mitogen-activated protein kinases and the phosphatidylinositol 3-kinase. Hyper-activated signaling through the ErbB-signaling network results in dysregulation of the cell cycle homeostatic machinery, with upregulation of active cyclin-D/CDK complexes. Recent data indicate that cell cycle regulators are also linked to chemoresistance in ErbB2-dependent breast carcinoma. Together with D-type cyclins, it seems that the CDK inhibitor p21Waf1 plays an important role in evasion from apoptosis. These recent findings herald a preliminary understanding of the output layer which connects elevated ErbB-signaling to oncogenesis and chemoresistance.
Overexpression of ErbB2, a receptor-like tyrosine kinase, is shared by several types of human carcinomas. In breast tumors the extent of overexpression has a prognostic value, thus identifying the oncoprotein as a target for therapeutic strategies. Already, antibodies to ErbB2 are used in combination with chemotherapy in the treatment of metastasizing breast cancer. The mechanisms underlying the oncogenic action of ErbB2 involve a complex network in which ErbB2 acts as a ligand-less signaling subunit of three other receptors that directly bind a large repertoire of stroma-derived growth factors. The major partners of ErbB2 in carcinomas are ErbB1 (also called EGFR) and ErbB3, a kinase-defective receptor whose potent mitogenic action is activated in the context of heterodimeric complexes. Why ErbB2-containing heterodimers are relatively oncopotent is a function of a number of processes. Apparently, these heterodimers evade normal inactivation processes, by decreasing the rate of ligand dissociation, internalizing relatively slowly and avoiding the degradative pathway by returning to the cell surface. On the other hand, the heterodimers strongly recruit survival and mitogenic pathways such as the mitogen-activated protein kinases and the phosphatidylinositol 3-kinase. Hyper-activated signaling through the ErbB-signaling network results in dysregulation of the cell cycle homeostatic machinery, with upregulation of active cyclin-D/CDK complexes. Recent data indicate that cell cycle regulators are also linked to chemoresistance in ErbB2-dependent breast carcinoma. Together with D-type cyclins, it seems that the CDK inhibitor p21Waf1 plays an important role in evasion from apoptosis. These recent findings herald a preliminary understanding of the output layer which connects elevated ErbB-signaling to oncogenesis and chemoresistance.
Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di FP and Kraus MH. . 1995 Oncogene 10: 1813-1821.
10.1093/emboj/16.18.5608 Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M and Pierce JH. . 1997 EMBO J. 16: 5608-5617.
10.1002/(SICI)1096-9896(199710)183:2<188::AID-PATH898>3.0.CO;2-7 Barsky SH, Doberneck SA, Sternlicht MD, Grossman DA and Love SM. . 1997 J. Pathol. 183: 188-194.
10.1200/JCO.1996.14.10.2702 Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR and De Placido S. . 1996 J. Clin. Oncol. 14: 2702-2708.
10.1002/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.0.CO;2-X Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R and Theillet C. . 1996 Int. J. Cancer 69: 247-253.
10.1016/S0959-8049(05)80010-3 Gasparini G, Gullick WJ, Maluta S, Dalla PP, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine NR and Bevilacqua P. . 1994 Eur. J. Cancer 30A: 16-22.
10.1002/ijc.2910630417 Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H and Dittrich C. . 1995 Int. J. Cancer 63: 560-567.
10.1073/pnas.85.14.5102 Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A and Shepard HM. . 1988 Proc. Natl. Acad. Sci. USA 85: 5102-5106.
10.1128/MCB.20.2.672-683.2000 Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines III GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ and Pestell RG. . 2000 Mol. Cell. Biol. 20: 672-683.
10.1038/bjc.1992.420 Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ and Hurst HC. . 1992 Br. J. Cancer 66: 1116-1121.
Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ and Yarden Y. . 1998 EMBO J. 17: 3385-3397.
10.1016/S1097-2765(00)80231-2 Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S and Yarden Y. . 1999 Mol. Cell 4: 1029-1040.
10.1038/bjc.1991.30 Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR and Harris AL. . 1991 Br. J. Cancer 63: 146-150.
O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr AJ and Kohn KW. . 1997 Cancer Res. 57: 4285-4300.
10.1073/pnas.95.18.10842 O'Rourke DM, Kao GD, Singh N, Park BW, Muschel RJ, Wu CJ and Greene MI. . 1998 Proc. Natl. Acad. Sci. USA 95: 10842-10847.
10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0 Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De LM, De PS, Giordano T, Merino M, Salomon DS, Mullich WJ, Pettinato G, Scnnitt SJ, Bianco AR and Ciardiello F. . 1996 Int. J. Cancer 65: 51-56.
Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ and Slamon DJ. . 1999 Cancer Res. 59: 1347-1355.
10.1038/sj.onc.1201642 Pinkas KR, Lenferink AE, Bacus SS, Lyass L, van de Poll MI, Klapper LN, Tzahar E, Sela M, van ZE and Yarden Y. . 1998 Oncogene 16: 1249-1258.
10.1128/MCB.18.10.6090 Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y and Alamandi M. . 1998 Mol. Cell. Biol. 18: 6090-6101.
10.1002/j.1460-2075.1996.tb00603.x Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Barry RJ, Sela M and Yarden Y. . 1996a EMBO J. 15: 2452-2467.
10.1002/j.1460-2075.1996.tb00603.x Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M and Yarden Y. . 1996b EMBO J. 15: 2452-2467.
Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC and Yarden Y. . 1998 EMBO J. 17: 5948-5963.
Tzahar E, Pinkas KR, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC and Yarden Y. . 1997 EMBO J. 16: 4938-4950.
10.1128/MCB.16.10.5276 Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y. . 1996 Mol. Cell. Biol. 16: 5276-5287.
10.1038/309418a0 Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD and Seeburg PH. . 1984 Nature 309: 418-425.
10.1073/pnas.95.12.6809 Wang LM, Kuo A, Alimandi M, Veri MC, Lee CC, Kapoor V, Ellmore N, Chen XH and Pierce JH. . 1998 Proc. Natl. Acad. Sci. USA 95: 6809-6814.
10.1128/MCB.14.3.1909 Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, Janssen AM, Ben-Baruch N, Trollinger DB, Jacobsen VL, Meng SY, Lu HS, Hu S, Chang D, N YW, Yanigahra D, Koski RA and Yarden Y. . 1994 Mol. Cell. Biol. 14: 1909-1919.
Yu D, Liu B, Tan M, Li J, Wang SS and Hung MC. . 1996 Oncogene 13: 1359-1365.
10.1073/pnas.94.18.9562 Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J and Godowski PJ. . 1997 Proc. Natl. Acad. Sci. USA 94: 9562-9567.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.